started · updated
Lenacapavir antiviral approved for HIV prevention in Mexico and US
The Mexican regulatory agency Cofepris has authorized the sale and use of lenacapavir, an injectable antiviral used for HIV pre-exposure prophylaxis (PrEP). The medication is administered twice a year, offering a more convenient alternative to daily oral tablets. While the approval is welcomed by health advocates like the Network of People Affected by HIV (Repavih), officials noted that the drug does not protect against other sexually transmitted infections.
In the United States, the FDA has approved a generic version of lenacapavir produced by the Indian pharmaceutical company Dr. Reddy’s Laboratories. This generic version is intended to increase accessibility in low- and middle-income countries. Through a pricing agreement involving Unitaid, the Wits RHI institute, and the Clinton Health Access Initiative (CHAI), the treatment is expected to cost approximately 40 dollars per year per patient and will be available in 120 countries.
Lenacapavir, originally developed by Gilead, has been shown to reduce the risk of HIV transmission by 99.9%. The availability of the generic version aims to address the high costs associated with the original brand-name drug.
Entities
Cofepris · Dr. Reddy’s Laboratories · FDA · Gilead · Unitaid